HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
A stock expert still thinks Seaport Therapeutics is a good company and believes its stock could be worth $50 per share someday. This means the expert sees reasons to feel hopeful about the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.